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Infection with Brucella causes brucellosis, a chronic disease in humans, which induces abortion and sterility in livestock. 
Among the different Brucella species, Brucella melitensis is considered the most virulent and is the predominant species asso-
ciated with outbreaks in China. To date, no safe human vaccine is available against Brucella infection. The currently used live 
vaccines against Brucella in livestock induce antibodies that interfere with the diagnosis of field infection in vaccinated ani-
mals, which is harmful to eradication programs. However, there is as yet no complete profile of immunogenic proteins of B. 
melitensis. Towards the development of a safer, equally efficacious, and field infection-distinguishable vaccine, we used im-
munoproteomics to identify novel candidate immunogenic proteins from B. melitensis M5. Eighty-eight immunoreactive pro-
tein spots from B. melitensis M5 were identified by Western blotting and were assigned to sixty-one proteins by mass spec-
trometry, including many new immunoreactive proteins such as elongation factor G, F0F1 ATP synthase subunit beta, and 
OMP1. These provide many candidate immunoreactive proteins for vaccine development. 
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Brucella are Gram-negative, nonspore-forming, nonmotile, 
and nonencapsulated coccobaccilli that occasionally cause 
brucellosis, also known as undulant fever, a chronic and 
debilitating febrile disease in humans that frequently induc-
es abortion and sterility in domestic and wild animals. Hu-
man infection can result from either occupational contact or 
ingestion of contaminated food [1]. The incidence of human 
and animal brucellosis worldwide has increased rapidly 
since 1995. In China, B. melitensis is the predominant strain 
associated with outbreaks [2]. 
Based on pathogenicity and host preference, eight spe-
cies have been identified within the genus: B. melitensis, B. 
abortus, B. suis, B. canis, B. cetacea, B. pinnipedia, B. neo-
tomae, and B. ovis [3]. Humans can become infected with B. 
melitensis, B. abortus, B. suis, and rarely, B. canis, B. pin-
nipedia, and B. cetacea. Among the different Brucella spe-
cies, B. melitensis is considered the most virulent. 
In livestock, brucellosis used to be partly controlled by 
conventional vaccines. Live, attenuated vaccines such as 
M5 and S2 have been used in animals in China; however, 
they are considered unsafe for humans as they can induce 
abortion in pregnant animals [2]. Development of the next 
generation of vaccines that are free from the drawbacks of 
the conventional vaccines requires the identification of 
Brucella antigens that can elicit a protective immune re-
sponse [4]. 
The diagnosis of brucellosis is mainly based on the de-
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tection of anti-lipopolysaccharide antibodies, and the cur-
rently used live vaccines against Brucella in livestock in-
duce high amounts of anti-lipopolysaccharide antibodies 
that interfere with the diagnosis of field infection in vac-
cinated animals [5]. Hence, the development of diagnostic 
assays based on more specific protein antigens is essential. 
It is very important that the live vaccines are revised to tar-
get a specific diagnostic protein antigen, which can distin-
guish field infection and have no effects on their protective 
efficacy in vaccinated animals. 
Unfortunately, a definitive profile of immunogenic pro-
teins, especially the Brucella protective proteins, is not yet 
complete [6,7]. However, much of this information can be 
derived from immunoproteomics, a technique that shows 
promise for diagnostics and vaccine development [8,9]. 
Moreover, the sequencing and annotation of pathogen ge-
nomes paves the way for the identification of immunogenic 
proteins [10–12]. Initial work describing the Brucella pro-
teome and immunoproteomics has been reported. A global 
proteomic analysis of whole cells of B. melitensis 16M [13] 
and a comparative proteomic analysis of Rev 1 and 16M [14] 
have been performed; recently, immunoreactive soluble 
proteins of B. melitensis 16M have been identified by im-
munoproteomics using the sera of patients suffering from 
acute brucellosis [15]. Proteins that are located in the outer 
membrane of the cell envelope are of special interest since 
they can modify the host cell environment and mediate host 
cell-bacterial interactions [16]. Accumulated data have in-
dicated that the major protective antigens appear to be 
components of the cell envelope [6]. Here, using bovine 
anti-Brucella sera, the whole-cell soluble proteins and 
membrane proteins (MPs) were screened, and 88 protein 
spots from B. melitensis M5 were identified to be immuno-
reactive. 
1  Materials and methods 
1.1  Bacterial cell culture 
B. melitensis M5, a biotype I vaccine strain, was used. Stock 
samples stored at 70°C were inoculated in Tryptic Soy 
Broth (Becton Dickinson Company, Sparks, USA) and in-
cubated to stationary growth phase by vigorous shaking for 
16 h at 37°C. 
1.2  Isolation of whole-cell soluble proteins [17] 
Cells from 200-mL cultures in the stationary growth phase 
were harvested by centrifugation at 4000×g for 15 min at 
4°C. The pellets were washed twice with low-salt washing 
sample buffer (3 mmol L–1 KCl, 1.5 mmol L1 KH2PO4, 68 
mmol L1 NaCl, 9 mmol L1 NaH2PO4) and resuspended in 
sonication buffer (8 mol L1 urea, 1% dithiothreitol, 4% 
CHAPS, 100 U Benzonase, and a tablet of complete prote-
ase inhibitor cocktail) and then sonicated on ice. The solu-
tion was kept at room temperature for 1 h and centrifuged at 
12000×g for 1 h. The supernatant was collected and stored 
at –70°C. 
1.3  Isolation and purification of MPs [18] 
After washing, harvested cells were resuspended in 100 mL 
buffer I (15 mmol L1 Tris-HCl pH 8.0, 0.45 mol L1 su-
crose, 8 mmol L1 EDTA, and 0.4 mg mL1 lysozyme). The 
samples were incubated for 4 h at 4°C, centrifuged at 
8000×g for 15 min, and resuspended in 3 mL buffer II (50 
mmol L1 Tris-HCl pH 7.4 and a tablet of complete protease 
inhibitor cocktail). The samples were chilled on ice and 
sonicated. Then the samples were centrifuged twice at 
3000×g for 15 min to remove unbroken cells. Chilled 0.1 
mol L1 Na2CO3, pH 11.0 (27 mL) was added to the super-
natants, and they were vortexed and immersed in ice water 
for 1 h. The supernatants were then subjected to ultracen-
trifugation at 50000×g for 1 h. The pellets were resuspended 
in 20 mL buffer II and ultracentrifuged again at 50000×g for 
1 h. The pellets were resuspended in sample buffer (8 mol 
L1 urea, 1% dithiothreitol, 4% CHAPS, and a tablet of 
complete protease inhibitor cocktail) and stored at –70°C 
until required. 
1.4  Protein determination 
The total protein concentration was determined using a 
Bradford kit (Applygen Technologies, Inc., Beijing, China) 
with bovine serum albumin as the standard. All samples, 
including the standard, were dissolved in the same buffer. 
1.5  Western blotting 
The sample proteins (200 g) were separated by isoelectric 
focusing on 18-cm, pH 4–7 linear immobilized pH gradient 
(IPG) strips. After 12 h of rehydration at 30 V and 20°C, the 
following focusing parameters were applied: 50 A per 
strip, with 500, 2000, or 5000 V for 30 min, linear voltage 
increased from 5000 to 10000 V in 2 h, then maintained at 
10000 V for 8 h. After isoelectric focusing, IPG strips were 
equilibrated and applied onto 12% vertical slab SDS-poly-      
acrylamide gels of 19×18.5×0.1 cm3. Electrophoresis was 
performed at 20°C with a constant power supply in two 
steps: 20 mA/gel for 30 min then 30 mA/gel until the track-
ing dye reached the bottom of the gel. Gels were then 
stained with Coomassie Brilliant Blue R-250. The gels were 
scanned with an Imagescanner, and the images analyzed 
using version 5.0 of ImageMaster 2D Platinum software. 
Proteins were transferred to polyvinylidene fluoride 
membranes using a TE77 semi-dry transfer unit (0.8 mA 
cm2, 1 h), then non-specific binding sites on the mem-
branes were blocked for 90 min with 5% skimmed milk in 
Tris-buffered saline (TBS) at 37°C. Then, the membranes 
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were probed with a 1:1500 dilution of primary antibody for 
1 h at 37°C with gentle shaking. The primary antibody was 
a bovine anti-Brucella-positive serum pool, which was a 
mixture of 15 bovine anti-Brucella-positive sera with titers 
of more than 1:1600 by tube agglutination tests. The cows 
had never been immunized with any Brucella vaccine. The 
control antibody was an anti-Brucella-negative bovine se-
rum pool, which was a mixture of 23 anti-Brucella-negative 
bovine sera with tube agglutination titers of less than 1:10. 
The membranes were rinsed three times for 10 min each in 
0.1% TBS plus Tween 20, then incubated with peroxi-
dase-conjugated rabbit anti-bovine immunoglobulin at a 
dilution of 1:10000 in TBS containing 5% skimmed milk for 
1 h at 37°C. After washing, the blots were developed using 
enhanced chemiluminescence Western blotting detection 
reagents. The specific immunoreactive protein pattern was 
visualized on X-ray film. Three replicate blots were used for 
image analysis. 
1.6  In situ tryptic digestion, mass spectrometry (MS), 
and protein identification 
Coomassie-stained protein spots were excised from the gel 
and destained with 25 mmol L1 ammonium bicarbonate 
buffer containing 50% acetonitrile. The destained gel pieces 
were completely dried then rehydrated with 2 L of 20 
mmol L1 ammonium bicarbonate containing 20 ng trypsin. 
After overnight incubation at 37°C, the gels were dried then 
incubated at 40°C for 1 h in 8 L of 5% trifluoroacetic acid 
(TFA). The extract was transferred into a fresh microtube. 
A second, 1-h extraction step was performed at 30°C in 8 L 
of 2.5% TFA/50% acetonitrile, then the two extracts were 
combined, dried, and resolubilized with 3 L of 0.1% TFA. 
Matrix-assisted laser desorption/ionization–time-of-flight 
(MALDI-TOF) MS measurements were performed on a 
Bruker Reflex™ III instrument (Bruker Daltonik, Bremen, 
Germany) operating in reflection mode. The MALDI-TOF-      
MS analysis was performed at 20 kV accelerating voltage 
and 23 kV reflecting voltage. The peptide mass fingerprints 
were searched against the NCBInr database using the Mas-
cot search engine (http://www.matrixscience.com/search_ 
form_select.html). The search parameters used were: max-
imum of one missed cleavage by trypsin; oxidation of me-
thionine; carbamidomethyl modification of cysteine; 
charged state of +1; and mass tolerance of ±0.1 Da. Proba-
bility-based MOWSE scores greater than 75 were consid-
ered significant (P<0.05). For unambiguous identification of 
proteins, more than five peptides had to be matched and the 
sequence coverage had to be greater than 15%. 
2  Results 
Typical gel maps of the whole-cell soluble proteins and 
MPs are presented in Figures 1A and 2A. A total of 725 and  
 
Figure 1  The proteome and Western blot of soluble proteins of B. 
melitensis M5 in the pH range 4.0–7.0. A, Soluble proteins (200 μg) were 
focused with IPG strips and run on 12% SDS-polyacrylamide gels. The 
gels were stained with Coomassie Brilliant Blue R250 and scanned. B, The 
primary antibody was a 1:1500 dilution of a bovine anti-Brucella-positive 
serum pool. The immunoreactive spots detected by Western blotting are  
marked. No spots were positive for the control primary antibody. 
426 protein spots were detected for the whole-cell soluble 
proteins and MPs, respectively. Of these, 67 and 21 spots, 
respectively, were immunoreactive with the bovine an-
ti-Brucella-positive serum pool compared with the control 
anti-Brucella-negative serum pool (data not shown). These 
spots were named S1 to S67 and O1 to O21, respectively 
(Figures 1B and 2B, respectively). 
Seventy-nine proteins, representing the products of 61 
genes, were successfully identified. Tables 1 and 2 list the 
identified proteins from the whole-cell soluble protein and 
MP samples, respectively. According to TIGR function 
categories, these immunoreactive proteins are mainly in-
volved in protein fate (10/61), transport and binding (8/61),  
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Figure 2  The proteome and Western blot of MPs of B. melitensis M5 in 
the pH range 4.0–7.0. A, MPs (200 g) were focused with IPG strips and 
run on 12% SDS-polyacrylamide gels. The gels were stained with Coo-
massie Brilliant Blue R250 and scanned. B, The primary antibody was a 
1:1500 dilution of a bovine anti-Brucella-positive serum pool. The immu-
noreactive spots detected by Western blotting are marked. No spots were 
positive for the control primary antibody. 
energy metabolism (8/61), protein synthesis (6/61), and 
cellular processes (4/61). Among the 61 identified proteins, 
ten were theoretical cell envelope proteins. Interestingly, the 
immunoreactive proteins included eight known viru-
lence-related proteins, including OMP25, trigger factor, 
DnaK, glucose-6-phosphate 1-dehydrogenase, SSU riboso-
mal protein S1P, glutamine synthetase type I, acetolactate 
synthase 3 catalytic subunit, and threonine synthase [19]. 
3  Discussion 
There is a pressing need to develop novel vaccines and spe-
cific diagnostic assays to reduce the high incidence of bru-
cellosis worldwide. In this study, we used an immunopro-
teomic screen to identify many candidate B. melitensis an-
tigens for these purposes. 
Using immunoproteomics greatly improves the chances 
of discovering immunogenic proteins. We identified 61 
immunoreactive proteins in this study, many more than the 
32 proteins that were discovered in early protein studies 
using Edman sequencing or Western blotting before the 
genomes of the Brucella species had been completely se-
quenced [7]. To further improve the chances of identifying 
novel antigens, we carried out sub-proteomics. Besides the 
four common antigens, the MP sample contained eight an-
tigens that were not identified in the whole-cell soluble pro-
tein sample; this indicates that sub-proteomics can be used 
to decrease the complexity of the whole-cell soluble protein 
sample to improve the discovery of novel antigens [20]. 
Immunoproteomics has several drawbacks such that it 
cannot be used to identify all the immunoreactive proteins 
of Brucella. For example, the Brucella lumazine synthase 
protein has never been identified by immunoproteomics, but 
is known to be able to elicit an immune and protective re-
sponse against Brucella [21]. More importantly, different 
research groups have discovered very different spectra of 
immunoreactive proteins using immunoproteomics, because 
of the different protein samples and anti-Brucella sera used. 
For example, using an unabsorbed anti-B. abortus 1119-3 
killed whole-cell rabbit serum, Al Dahouk et al. [5] identi-
fied 17 immunoreactive protein spots out of the 383 protein 
spots of B. abortus 1119-3, which were assigned to six pro-
teins. In contrast, Teixeira-Gomes et al. [22] were able to 
identify 82 immunoreactive protein spots in a comparable 
protein sample preparation of B. ovis using the serum of a 
naturally infected ram. In another study, using antiserum 
collected from cows and a human accidentally infected with 
Brucella, 54 immunoreactive protein spots out of 332 pro-
tein spots in B. abortus CE were identified, which were as-
signed to 18 proteins [6]. Recently, 32 immunoreactive 
protein spots assigned to 27 proteins among the soluble 
proteins of B. melitensis 16M were identified using the sera 
of patients suffering from acute brucellosis [15]. In this 
study, we identified 88 immunoreactive protein spots as-
signed to 61 proteins out of 1151 protein spots. The higher 
number of proteins we identified suggests that using an anti-     
Brucella-positive serum pool can improve the chances of 
identification. Of the 61 immunoreactive proteins in our 
study, only 4, 5, 9, and 3 proteins are in common with those 
identified by Al Dahouk et al. [5], Teixeira-Gomes et al. [22], 
Connolly et al. [6], and Yang et al. [15], respectively. 
Therefore, all the proteins identified by immunoproteomics 
need further validation and evaluation by other groups and 
methods. Of course, live Brucella dynamically adjusts its 
protein expression profile for survival in the host and it may 
change enormously during the course of infection [23]. 
Some proteins may not be expressed under laboratory con- 
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Table 1  Immunoreactive soluble proteins from B. melitensis M5 as determined by Western blotting and MALDI-TOF-MS 
Spot No.a) Protein identification Locus MOWSE scoreb) Sequence coverage (%) Peptides matched 
Cell envelope 
S2 OMP28/BP26 BMEI0536 75 40 6 
S10 UDP-N-acetylmuramoylalanyl-D- 
glutamate-2,6-diaminopimelate ligase 
BMEI0574 130 28 9 
S12, S15 OMP1 BMEI0830 125, 137 32, 26 17, 14 
S60 31 kD immunogenic protein precursor BMEI0796 86 22 6 
S65 Porin BMEI1305 83 31 7 
S58 OMP25c BMEI1829 75 35 6 
Cellular processes 
S1, S51 DNA protection during starvation protein BMEI1980 109, 92 36, 44 6, 7 
S9 Branched-chain alpha-keto acid dehydro-
genase subunit E2 
BMEII0746 116 25 9 
S14 Cell division protein FtsZ BMEI0585 204 24 9 
S64 Cell division inhibitor minD BMEII0926 89 35 8 
Protein fate 
S18 Molecular chaperone DnaK BMEI2002 125 15 9 
S57 DnaK BMEI1549 223 25 16 
S19, S45 Chaperonin GroEL BMEII1048 210, 174 15, 28 9, 18 
S20 HtrA BMEI1330 137 19 8 
S26 Acriflavin resistance protein A precursor BMEI1630 174 21 7 
S35 Leucyl aminopeptidase BMEI1261 139 23 9 
S48 GrpE protein BMEI1777 126 31 7 
S50 Peptidyl-prolyl cis-trans isomerase A BMEI0888 138 39 6 
S59 Protein-L- 
Isoaspartate O-methyltransferase 
BMEI1030 180 24 6 
Transport and binding proteins 
S28 Periplasmic oligopeptide-binding protein 
precursor 
BMEII0735 214 27 14 
S29 Metal chelate periplasmic binding protein BMEI0658 155 29 8 
S30 Trehalose/maltose- 
Binding protein 
BMEI1716 89 21 6 
S31 Leu/Ile/Val-binding protein precursor BMEII0103 137 28 7 
S32 Periplasmic oligopeptide-binding protein 
precursor 
BMEII0735 88 25 10 
S42 Putrescine-binding protein, putative BMEI0411 103 24 6 
S43 Iron(III)-binding periplasmic protein pre-
cursor 
BMEII1120 128 59 19 
S67 D-galactose-binding periplasmic protein 
precursor 
BMEII0983 135 49 13 
Energy metabolism 
S3 Lactoylglutathione lyase BMEI0730 108 41 7 
S8 Glucose-6-phosphate 1-dehydrogenase BMEII0513 217 30 13 
S11 F0F1 ATP synthase subunit beta BMEI0251 239 36 12 
S36 F0F1 ATP synthase subunit alpha BMEI0249 148 23 11 
S38 Transketolase BMEI 0311 223 28 22 
S41 Enolase BMEI0851 147 20 8 
S47 Electron transfer flavoprotein, 
alpha subunit 
BMEI0097 75 49 5 
S13 Acetyl/propionyl-CoA carboxylase alpha 
chain 
BMEI1925 281 58 19 
Central intermediary metabolism 
S46 Putative thiosulfate sulfurtransferase BMEI0931 175 19 9 
S61 2,5-diketo-D-gluconic acid reductase BMEII1060 168 52 15 
DNA metabolism 
S52 DnaK suppressor protein homolog BMEI0949 85 45 5 
Protein synthesis 
S16 Elongation factor G BMEI0754 174 24 13 
S27 Histidyl-tRNA synthetase BMEII1056 135 27 11 
(To be continued on the next page)
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(Continued)
Spot No.a) Protein identification Locus MOWSE scoreb) Sequence coverage (%) Peptides matched 
S53 Ribosome recycling factor BMEI0826 95 41 6 
S55 SSU ribosomal protein S1P BMEI1915 116 16 9 
S66 Protein translation elongation factor Ts 
(EF-Ts) 
BMEI0824 157 64 16 
Amino acid biosynthesis 
S21 Glutamine synthetase type I BMEI0979 213 25 11 
S34 Acetolactate synthase 3 catalytic subunit BMEI0617 189 21 9 
S24 Threonine synthase BMEI1450 179 57 15 
Biosynthesis of cofactors, prosthetic groups and carriers 
S40 GTP cyclohydrolase 
II/3,4-dihydroxy-2-butanone 4-phosphate 
synthase 
BMEI1505 145 42 17 
S62 2,3,4,5-tetrahydropyridine-2-carboxylateN-
succinyltransferase 
BMEII0270 99 16 5 
Fatty acid and phospholipid metabolism 
S23 3-oxoacyl-(acyl carrier protein) synthase II BMEI1473 136 51 13 
S39 Acetyl-CoA carboxylase biotin carbox-
ylase 
BMEI1063 157 39 12 
S63 Acetyl-CoA carboxylase carboxyltransfer-
ase subunit alpha 




BMEI1961 183 17 9 
Unclassified 
S37 Electron transfer flavoprotein-ubiquinone 
oxidoreductase precursor 
BMEI1320 218 31 16 
Not determined 
S4, S5, S6, S7, S22, 
S25, S49, S54, S56 
 
a) Spot numbers refer to the numbers on the gel shown in Figure 1A. b) Protein scores greater than 75 are significant (P<0.05). 
Table 2  Immunoreactive MPs from B. melitensis M5 as determined by Western blotting and MALDI-TOF-MS 











O8, O12 Iron-regulated outer membrane protein FRPB BMEII0105 153, 180 42, 45 30, 31 
O13 Bacterial surface antigen (D15) BMEI1895 218 77 40 
O15, O16 OMP25 BMEI1249 83, 101 38, 62 12, 16 
O17, O19 OMP25b BMEI1007 76, 93 25, 25 5, 5 
Protein fate 







O10 Trigger factor BMEI1069 82 41 23 
Energy metabolism 
O11 ATP synthase subunit B BMEI0251 128 67 28 
O20 Acetyl/propionyl-CoA carboxylase Alpha chain BMEI1925 93 38 26 
Protein synthesis 
O18 50S ribosomal protein BMEI0748 61 58 5 




BMEI1264 168, 150 51, 51 39, 42 
Unknown 
O14 Hypothetical protein BMEI0178 85 65 11 
a) Spot numbers refer to the numbers on the gel shown in Figure 2A. b) Protein scores greater than 75 are significant (P<0.05). 
 
 
ditions. Furthermore, even under common laboratory condi-
tions, the protein expression profile of B. melitensis is dif-
ferent from that of B. abortus [24]. The production of anti-
bodies directed against specific proteins may be host-specific. 
Some proteins are highly immunogenic in one type of ani-
mal but fail to show any immunogenicity in other animal 
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types. Anti-OMP28 (BP26) antibodies were detected in 
Brucella-infected humans and goats, but not in pigs and 
cattle [25]. Additionally, the kinetics of the serum antibody 
response to Brucella proteins may reflect the different stag-
es of infection. Antibodies to BP26 were found only in the 
sera of patients suffering from acute brucellosis [26]. 
The complete profile of immunoreactive proteins will ul-
timately help to understand the interesting biology of differ-
ent Brucella species, such as their virulence and host prefer-
ence. Considering our data and those of Connolly et al. [6], it 
is likely that the presence of ribosomal proteins in the mem-
brane preparations from prokaryotes genuinely indicates 
their localization at the membrane, rather than contamina-
tion by cytosolic proteins [27,28]. OMP25 belongs to the 
OMP A protein family, which accounts for 30%–40% of the 
outer membrane. In the genome of B. melitensis, four 
OMP25 genes are predicted: BMEI1249, BMEI1007, 
BMEI1829, and BMEI1830, of which three (BMEI1249, 
BMEI1007, and BMEI1829) were identified in this study. 
Importantly, OMP25 is an immune response regulator and 
may mediate inhibition of the host cell production of tumor 
necrosis factor alpha [29]. Mutants of B. melitensis, B. 
abortus, and B. ovis strains with the OMP25 gene inacti-
vated have been found to be attenuated in mice, goats, and 
cattle [30–32]. Heat shock proteins are vital for Brucella 
survival under various harsh conditions; these were identi-
fied in almost all immunoproteomic studies. The blockage 
of heat shock protein function by antibodies may be an im-
portant host protection strategy. HtrA is generally thought 
to serve as a stress response protease in the periplasmic 
space and has been shown to be important for adaption to 
the intracellular environment of host macrophages [33,34]. 
DnaK is important for Brucella growth and survival under 
stress conditions: A constitutive DnaK mutant failed to mul-
tiply in murine macrophages and was rapidly eliminated [35]. 
Trigger factor is an ATP-independent chaperone that binds to 
the nascent polypeptide chain [36]. Recently trigger factor 
was revealed to be a protective antigen against brucellosis 
[37]. In addition, the proteins involved in energy metabo-
lism, iron acquisition [14], and protein synthesis may be 
vital for Brucella survival, some of which were also identi-
fied to be immunoreactive in this study. Recently, recombi-
nant S-adenosyl-L-homocysteine hydrolase has been shown 
to stimulate the production of interferon gamma and induce 
a high level of protection against B. melitensis [15]. 
In summary, we discovered 61 immunoreactive proteins 
from among the whole-cell soluble proteins and MPs of B. 
melitensis M5. These data will help to develop novel vac-
cines and specific diagnostic assays in the future. At present, 
validation of these proteins’ immunoreactivity and investi-
gation of their protective efficacy is in progress. Twelve of 
them have been validated as immunogenic, including the 
iron-regulated outer membrane protein FRPB (BMEII0105) 
and grpE protein (BMEI1777). Using anti-Brucella sera 
collected from animals and humans accidentally infected 
with different species of Brucella, all the novel immunore-
active proteins of the various Brucella species will gradual-
ly be discovered and investigated. 
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